ShockWave Medical, Inc. (SWAV): Price and Financial Metrics

ShockWave Medical, Inc. (SWAV): $197.78

3.61 (+1.86%)

POWR Rating

Component Grades














  • Growth is the dimension where SWAV ranks best; there it ranks ahead of 69.78% of US stocks.
  • The strongest trend for SWAV is in Stability, which has been heading down over the past 31 weeks.
  • SWAV ranks lowest in Stability; there it ranks in the 6th percentile.

SWAV Stock Summary

  • Shockwave Medical Inc's stock had its IPO on March 7, 2019, making it an older stock than just 5.22% of US equities in our set.
  • SWAV's price/sales ratio is 80.39; that's higher than the P/S ratio of 95.94% of US stocks.
  • As for revenue growth, note that SWAV's revenue has grown 66.15% over the past 12 months; that beats the revenue growth of 91.48% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Shockwave Medical Inc, a group of peers worth examining would be BLDP, INSP, PHR, STXS, and CVLT.
  • Visit SWAV's SEC page to see the company's official filings. To visit the company's web site, go to

SWAV Price Target

For more insight on analysts targets of SWAV, see our SWAV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $176.20 Average Broker Recommendation 1.5 (Moderate Buy)

SWAV Stock Price Chart Interactive Chart >

Price chart for SWAV

SWAV Price/Volume Stats

Current price $197.78 52-week high $201.13
Prev. close $194.17 52-week low $41.77
Day low $197.03 Volume 95,270
Day high $201.13 Avg. volume 423,689
50-day MA $166.45 Dividend yield N/A
200-day MA $117.60 Market Cap 6.92B

ShockWave Medical, Inc. (SWAV) Company Bio

Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

SWAV Latest News Stream

Event/Time News Detail
Loading, please wait...

SWAV Latest Social Stream

Loading social stream, please wait...

View Full SWAV Social Stream

Latest SWAV News From Around the Web

Below are the latest news stories about Shockwave Medical Inc that investors may wish to consider to help them evaluate SWAV as an investment opportunity.

ShockWave Medical, Inc.'s (NASDAQ:SWAV) Path To Profitability

We feel now is a pretty good time to analyse ShockWave Medical, Inc.'s ( NASDAQ:SWAV ) business as it appears the...

Yahoo | May 18, 2021

Why Shockwave Medical Stock Jumped Today

The health tech specialist could save lives -- and deliver impressive growth to shareholders along the way.

Yahoo | May 12, 2021

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q1 2021 Results - Earnings Call Transcript

ShockWave Medical, Inc. (SWAV) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Debbie Kaster - Vice President, Investor Relations Doug Godshall - President and Chief Executive Officer Isaac Zacharias - Chief Commercial Officer Dan Puckett - Chief Financial Officer Conference Call Participants Larry Biegelsen -...

SA Transcripts on Seeking Alpha | May 11, 2021

Shockwave Medical Stock Jumps On Q1 Revenue Growth, Analyst Upgrades

Shockwave Medical Inc (NSDQ: SWAV) first-quarter FY21 sales more than double to $31.9 million beating the Wall Street consensus of $29.9 million. The growth was primarily driven by the launch of the coronary product, Shockwave C, in the U.S. in February and increased adoption of Shockwave products. The company posted a Q1 EPS loss of ($0.68), which missed the analyst consensus estimate of ($0.45) loss. The loss was wider than ($0.59) reported a year ago. Guidance: Shockwave Medical projects FY revenue of $195 million to $205 million, well above the consensus of $158.9 million. Analyst Upgrade: After strong Q1 earnings, analysts have upgraded the stock and raised the target price for the company. Wells Fargo analyst Lawrence Biegelsen raised the price target to $161 from $151 and kept an...

Yahoo | May 11, 2021

ShockWave Medical Inc (SWAV) Q1 2021 Earnings Call Transcript

SWAV earnings call for the period ending March 31, 2021.

Yahoo | May 11, 2021

Read More 'SWAV' Stories Here

SWAV Price Returns

1-mo 12.26%
3-mo 89.35%
6-mo N/A
1-year 340.44%
3-year N/A
5-year N/A
YTD 90.69%
2020 136.16%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8907 seconds.